<html><body><h2>Case: 547332</h2><h3> CDS Time: 1978-03-10</h3>
<patient name=547332>
78.0 year old Hispanic Male
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">78</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">UrineProtein_12h</td><td width="200">110</td><td width="200">1975-5-30</td></tr>
<tr><td width="200">Calcium</td><td width="200">10</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">UrineProtein_24h</td><td width="200">110</td><td width="200">1975-5-30</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">101</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">4</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">81</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Chloride</td><td width="200">102.0</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">39</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">64</td><td width="200">1978-3-10</td></tr>
<tr><td width="200">BNP</td><td width="200">7416.0</td><td width="200">1978-2-16</td></tr>
<tr><td width="200">Weight</td><td width="200">164</td><td width="200">1978-3-10</td></tr>
<tr><td width="200">HbA1C</td><td width="200">6</td><td width="200">1978-1-30</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">80</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Urine_ALB/CREAT_RATIO_spot</td><td width="200">294</td><td width="200">1974-10-26</td></tr>
<tr><td width="200">Urine_Alb/creat_Ratio_24h</td><td width="200">294</td><td width="200">1974-10-26</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">128</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">SGOT</td><td width="200">17</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">130</td><td width="200">1978-3-10</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">1</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Height</td><td width="200">70</td><td width="200">1977-3-16</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">128</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">BUN</td><td width="200">25</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">HCT</td><td width="200">42</td><td width="200">1977-8-3</td></tr>
<tr><td width="200">HGB</td><td width="200">14</td><td width="200">1977-8-3</td></tr>
<tr><td width="200">Sodium</td><td width="200">141</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.9</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">UrineAlbumin_24H</td><td width="200">659</td><td width="200">1974-10-26</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">6</td><td width="200">1978-1-30</td></tr>
<tr><td width="200">UrineProtein_Qualitative</td><td width="200">110.0</td><td width="200">1975-5-30</td></tr>
<tr><td width="200">UrineProtein_Spot</td><td width="200">110</td><td width="200">1975-5-30</td></tr>
<tr><td width="200">UrineAlbumin_SPOT</td><td width="200">659</td><td width="200">1974-10-26</td></tr>
<tr><td width="200">Pulse</td><td width="200">55</td><td width="200">1978-3-10</td></tr>
<tr><td width="200">PLT</td><td width="200">160</td><td width="200">1977-8-3</td></tr>
<tr><td width="200">WBC</td><td width="200">7</td><td width="200">1977-8-3</td></tr>
<tr><td width="200">eGFR</td><td width="200">37</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1978-2-16</td></tr>
<tr><td width="200">SGPT</td><td width="200">25</td><td width="200">1978-3-8</td></tr>
<tr><td width="200">tobacco use</td><td width="200"></td><td width="200">1977-2-5</td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1978-2-16</td></tr>
<tr><td width="200">smoking</td><td width="200"></td><td width="200">1977-2-5</td></tr>
<tr><td width="200">Heart_Failure</td><td width="200"></td><td width="200">1978-1-30</td></tr>
<tr><td width="200">Hyperlipidemia</td><td width="200"></td><td width="200">1978-3-10</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1978-2-16</td></tr>
<tr><td width="200">Bronchospastic_Disease</td><td width="200"></td><td width="200">1978-2-3</td></tr>
<tr><td width="200">PVD</td><td width="200"></td><td width="200">1977-1-17</td></tr>
<tr><td width="200">Angina</td><td width="200"></td><td width="200">1978-3-10</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1978-3-10</td></tr>
<tr><td width="200">othopnea</td><td width="200"></td><td width="200">1978-1-30</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1978-3-10</td></tr>
<tr><td width="200">Tobacco_Use</td><td width="200"></td><td width="200">1977-2-5</td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
<tr><td width="200">Race</td><td width="200">Hispanic</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> glyburide(2.5) aspirin(81.0) metformin(1700.0) terazosin(2.0) atenolol(100.0) lisinopril(40.0) hydrochlorothiazide(25.0) furosemide(40.0) pravastatin(40.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">CRI</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(1.9/1978-3-8) && Sex(Male) && Creatinine(1.9/1978-3-8)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of angina]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(39.0/1978-3-8)]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">Heart Failure  (Secondary Prev) BP controlled</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary Prevention)[Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null) && presence of heart failure]()</td></tr>
<tr><td width="200">Heart Failure (second prev) BP cont</td>
<td width="200"></td>
<td width="200"> Heart Failure (Secondary prevention)[Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null) && heart failure present]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Age(78.0/1970-1-1) && Sex(Male)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(37.0/1978-3-8)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(37.0/1978-3-8)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[taking furosemide && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Active prescription for thiazide</td>
<td width="200"></td>
<td width="200"> active prescription for thiazide[presence of thiazide diuretics]()</td></tr>
<tr><td width="200">active prescription for furosemide</td>
<td width="200"></td>
<td width="200"> active prescription for furosemide[taking furosemide]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(78.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">CCS-7.4</td>
<td width="200">1977-01-17</td>
<td width="200"> PVD()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1978-01-30</td>
<td width="200"> Heart_Failure()</td></tr>
<tr> <td width="200"></td>
<td width="200">1978-03-10</td>
<td width="200"> Angina()</td></tr>
<tr> <td width="200"></td>
<td width="200">1978-03-10</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1978-02-16</td>
<td width="200"> Hypertension()</td></tr>
<tr><td width="200">Psychiatric_Diseases</td>
<td width="200">1977-02-05</td>
<td width="200"> Tobacco_Use()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">1978-03-10</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1978-02-16</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Respiratory_Diseases</td>
<td width="200">1978-02-03</td>
<td width="200"> Bronchospastic_Disease()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1978-01-30</td>
<td width="200"> othopnea()
<tr> <td width="200"></td>
<td width="200">1978-03-10</td>
<td width="200"> Hyperlipidemia()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200">1977-02-05</td>
<td width="200"> tobacco use()
<tr> <td width="200"></td>
<td width="200">1977-02-05</td>
<td width="200"> smoking()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
</patient>
<h1 align="center">VA/JNC-VII Hypertension Guideline</h1>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(presence of diagnosis of hypertension && absence of renovascular disease && no diagnosis of pregnancy && Absense of Secondary Hypertension && absence of spinal cord injury && absence of narcolepsy && Not taking cyclosporine && Not taking spironolactone && Not taking minoxidil && absence of renovascular disease && absence of IHSS && Absence of Ascites && Not off guideline && not taking tacrolimus && absence of transplant recipient && Absence of a dialysis procedure code)</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of DM)</i>]
</ul>
<b>Scenario choice:</b> on four anti-hypertensive drugs
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li>Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist. Please monitor patient carefully if maintaining beta adrenergic receptor antagonist.
<li>This patient has an active prescription for an alpha adrenergic antagonist. We assume that you have checked the patient's standing blood pressure and that the patient does not have orthostasis (for example, SBP drop >20 mmHg).
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>It is false that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: lisinopril, hydrochlorothiazide, atenolol, furosemide, terazosin
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Please evaluate carefully if maintaining patient on beta adrenergic receptor antagonist or increasing the dose.
<li>Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.
</ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>creatinine > ULN, check creatinine <font color=FF0000>preferred</font></b>(rule in criterion<i> creatinine > upper limit of normal</i> evaluate to <b> true</b> because <i>Creatinine(1.9/1978-3-8)</i>)])
Warning: creatinine value is greater than 1.5 mg/dL, upper limit of normal for males.
<li><b>tobacco being used, encourage smoking cessation <font color=FF0000>preferred</font></b>(rule in criterion<i> tobacco use</i> evaluate to <b> true</b> because <i>tobacco use</i>)])
If patient is still smoking, please encourage smoking cessation
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>Beta blocker and diabetes <font color=FF0000>preferred</font></b>(rule in criterion<i> On beta blocker and DM</i> evaluate to <b> true</b> because <i>presence of DM && beta blocker being used</i>)])
Beta blockers may mask symptoms of hypoglycemia and should be used with caution.
<li><b>primary Beta blocker Bronchospastic DX <font color=FF0000>preferred</font></b>(rule in criterion<i> betablocker and bronchospasm</i> evaluate to <b> true</b> because <i>Presence of bronchspasm && beta blocker being used</i>)])
Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Please evaluate carefully if maintaining patient on beta adrenergic receptor antagonist or increasing the dose.
Bronchospasm may be a STRONG CONTRAINDICATION for use of beta adrenergic receptor antagonists, although many patients tolerate and therefore benefit from this drug therapy. Consider the possibility of bronchospasm, particularly if you increase the dose of beta adrenergic receptor antagonist. Please monitor patient carefully if maintaining beta adrenergic receptor antagonist.
<li><b>Beta blocker and PVD <font color=FF0000>preferred</font></b>(rule in criterion<i> ON Beta blocker and PVD</i> evaluate to <b> true</b> because <i>presence of PVD && beta blocker being used</i>)])
Beta blockers may exacerbate symptoms of peripheral vascular disease.  It is important to ask about this potential side effect in your treated patient. 
<li><b>alpha blocker orthostasis <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of alpha blocker</i> evaluate to <b> true</b> because <i>presence of alpha blocker</i>)])
This patient has an active prescription for an alpha adrenergic antagonist. We assume that you have checked the patient's standing blood pressure and that the patient does not have orthostasis (for example, SBP drop >20 mmHg).
<li><b>On beta blocker hyperlipidemia <font color=FF0000>preferred</font></b>(rule in criterion<i> beta blocker being used</i> evaluate to <b> true</b> because <i>beta blocker being used</i>)])
Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is false that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: lisinopril, hydrochlorothiazide, atenolol, furosemide, terazosin
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>four drug-therapy-choices</b><br>
<ul>
<li><b>substituting drug <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No constraindicated drug and (BP adequately controlled but compellingly indicated drug not given) </i> evaluate to <b> true</b> because <i>Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null) && there exists a compellingly indicated drug that is not already given && there exists a non-betablocker, non-ACE, non-clonidine , non (alpha blocker + BPH)drug to replace && (~B)no current drug contraindicatedthere exists a contraindicated current med</i>)])
Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.

</ul>
<li><b>substitution messages</b><br>
<ul>
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul><li> Substitution: replace <ul><li>terazosin(Alpha_blockers)<ul><li>Susbtituting away fom alpha blocker, no BPH?(We could not find a diagnosis of BPH. If there is a diagnosis of BPH please update the problem list and ignore this recommendation to substitute away from the alpha blocker.)</ul> with <li>ACE Inhibitor (lisinopril)<ul><li>Already being used<li><font color=FF0000>Compelling indications:  Heart_Failure(Heart_Failure)  Heart Failure  (Secondary Prev) BP controlled(Heart Failure (Secondary Prevention)[Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null) && presence of heart failure])  Diabetes_Mellitus(DM-Type2)  DM (2ary prev)  BP controlled(Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null) && presence of diabetes mellitus])  CKD by eGFR or ICD9 codes(CKD[eGFR(37.0/1978-3-8)]) </font><li>preference: ruled out</ul><li>Cardioselective Beta Blocker (atenolol)<ul><li>Already being used<li>Drugs to partner:  Thiazide_Diuretics(hydrochlorothiazide) <li><font color=FF0000>Compelling indications:  Heart_Failure(Heart_Failure)  Heart Failure (second prev) BP cont(Heart Failure (Secondary prevention)[Treatment_Diastolic_BP(64/null) && Treatment_Systolic_BP(130/null) && heart failure present]) </font><li>Relative indications:  Angina(Angina)  Coronary_Artery_Disease(Coronary_Artery_Disease)  CKD by eGFR or ICD9 codes(CKD[eGFR(37.0/1978-3-8)])  Diabetes_Mellitus(DM-Type2) <li>Relative contraindications:  Bronchospastic_Disease(Bronchospastic_Disease) <li>preference: ruled out</ul><li>DHP Calcium Channel Blocker (felodipine, nifedipine SA)<ul><li>Drugs to partner:  Beta-Blockers(atenolol) <li>Relative indications:  Angina(Angina)  Diabetes_Mellitus(DM-Type2) <li>preference: neutral</ul><li>(non-DHP) Calcium Channel Blocker (diltiazem)<ul><li>Drugs with bad interactions:  Beta-Blockers(atenolol) <li>Relative indications:  Angina(Angina)  CKD by eGFR or ICD9 codes(CKD[eGFR(37.0/1978-3-8)]) <li>Relative contraindications:  Heart_Failure(Heart_Failure) <li>preference: ruled out</ul><li>Potassium Sparing Diuretic <ul><li>preference: neutral<li>No comment</ul></ul></ul></body></html>